Effect of Glucagon-like Peptide 1 Receptor Agonists on Albuminuria in Adult Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

Overview

Journal Diabetes Obes Metab

Specialty Endocrinology

Date 2022 May 19

PMID 35589615

Authors

Daniel Yuan

Harman Sharma

Anirudh Krishnan

Venkat N Vangaveti

Usman H Malabu

Affiliations

Soon will be listed here.

Abstract

Aims: To determine the effect of glucagon-like peptide 1 receptor agonists (GLP-1RAs) on albuminuria in adult patients with type 2 diabetes mellitus (T2DM).

Methods: Medline Ovid, Scopus, Web of Science, EMCARE and CINAHL databases from database inception until 27 January 2022. Studies were eligible for inclusion if they were randomized controlled trials that involved treatment with a GLP-1RA in adult patients with T2DM and assessed the effect on albuminuria in each treatment arm. Data extraction was conducted independently by three individual reviewers. The PRISMA guidelines were followed regarding data extraction and quality assessment. Data were pooled using a random effects inverse variance model and all analysis was carried out with RevMan 5.4 software. The Jadad scoring tool was employed to assess the quality of evidence and risk of bias in the randomized controlled trials.

Results: The initial search revealed 2419 articles, of which 19 were included in this study. An additional three articles were identified from hand-searching references of included reviews. Therefore, in total, 22 articles comprising 39 714 patients were included. Meta-analysis suggested that use of GLP1-RAs was associated with a reduction in albuminuria in patients with T2DM (weighted mean difference -16.14%, 95% CI -18.42 to -13.86%; p < .0001) compared with controls.

Conclusions: This meta-analysis indicates that GLP-1RAs are associated with a significant reduction in albuminuria in adult patients with T2DM when compared with placebo.

Citing Articles

Acute hyperglycemia induces podocyte apoptosis by monocyte TNF-α release, a process attenuated by vitamin D and GLP-1 receptor agonists.

Zhang R, Oh J, Wice B, Dusso A, Bernal-Mizrachi C J Steroid Biochem Mol Biol. 2025; 247:106676.

PMID: 39818342 PMC: 11859504. DOI: 10.1016/j.jsbmb.2025.106676.

The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes: A Meta-Analysis of Randomized Placebo-Controlled Trials.

Mendonca L, Moura H, Chaves P, Neves J, Ferreira J Clin J Am Soc Nephrol. 2024; .

PMID: 39480988 PMC: 11835157. DOI: 10.2215/CJN.0000000584.

GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy.

Scheen A Drugs. 2024; 84(11):1347-1364.

PMID: 39342059 DOI: 10.1007/s40265-024-02090-9.

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists in the Management of Obesity-Related Heart Failure with Preserved Ejection Fraction: Benefits beyond What Scales Can Measure?.

Karakasis P, Fragakis N, Patoulias D, Theofilis P, Sagris M, Koufakis T Biomedicines. 2024; 12(9).

PMID: 39335625 PMC: 11429383. DOI: 10.3390/biomedicines12092112.

Albuminuria, Forgotten No More: Underlining the Emerging Role in CardioRenal Crosstalk.

Romero-Gonzalez G, Rodriguez-Chitiva N, Canameras C, Paul-Martinez J, Urrutia-Jou M, Troya M J Clin Med. 2024; 13(3).

PMID: 38337471 PMC: 10856688. DOI: 10.3390/jcm13030777.

References

Thomas M . The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. Diabetes Metab. 2017; 43 Suppl 1:2S20-2S27. DOI: 10.1016/S1262-3636(17)30069-1. View

Wang J, Li H, Xu X, Kong X, Sun R, Jing T . The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus. Biomed Res Int. 2020; 2019:2682657. PMC: 6943972. DOI: 10.1155/2019/2682657. View

Murphy K, Dhillo W, Bloom S . Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev. 2006; 27(7):719-27. DOI: 10.1210/er.2006-0028. View

Afkarian M, Sachs M, Kestenbaum B, Hirsch I, Tuttle K, Himmelfarb J . Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013; 24(2):302-8. PMC: 3559486. DOI: 10.1681/ASN.2012070718. View

Tonneijck L, Smits M, Muskiet M, Hoekstra T, Kramer M, Danser A . Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care. 2016; 39(11):2042-2050. DOI: 10.2337/dc16-1371. View

Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino M, Bellastella G . GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021; 20(1):189. PMC: 8442438. DOI: 10.1186/s12933-021-01366-8. View

Mann J, Orsted D, Brown-Frandsen K, Marso S, Poulter N, Rasmussen S . Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(9):839-848. DOI: 10.1056/NEJMoa1616011. View

Pfeffer M, Claggett B, Diaz R, Dickstein K, Gerstein H, Kober L . Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015; 373(23):2247-57. DOI: 10.1056/NEJMoa1509225. View

Derosa G, Cicero A, Franzetti I, Querci F, Carbone A, Ciccarelli L . Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy. Can J Physiol Pharmacol. 2013; 91(9):724-32. DOI: 10.1139/cjpp-2012-0300. View

10.

Holman R, Bethel M, Mentz R, Thompson V, Lokhnygina Y, Buse J . Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(13):1228-1239. PMC: 9792409. DOI: 10.1056/NEJMoa1612917. View

11.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

12.

Nakaguchi H, Kondo Y, Kyohara M, Konishi H, Oiwa K, Terauchi Y . Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study. J Diabetes Investig. 2020; 11(6):1542-1550. PMC: 7610130. DOI: 10.1111/jdi.13270. View

13.

Pratley R, Aroda V, Lingvay I, Ludemann J, Andreassen C, Navarria A . Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018; 6(4):275-286. DOI: 10.1016/S2213-8587(18)30024-X. View

14.

Bouchi R, Nakano Y, Fukuda T, Takeuchi T, Murakami M, Minami I . Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. Endocr J. 2016; 64(3):269-281. DOI: 10.1507/endocrj.EJ16-0449. View

15.

Norris K, Smoyer K, Rolland C, Van der Vaart J, Grubb E . Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review. BMC Nephrol. 2018; 19(1):36. PMC: 5807748. DOI: 10.1186/s12882-018-0821-9. View

16.

Tonneijck L, Muskiet M, Smits M, Hoekstra T, Kramer M, Danser A . Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial. Diabetes Obes Metab. 2017; 19(12):1669-1680. DOI: 10.1111/dom.12985. View

17.

Zhang F, Tong Y, Su N, Li Y, Tang L, Huang L . Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials. J Diabetes. 2014; 7(3):329-39. DOI: 10.1111/1753-0407.12198. View

18.

Mosenzon O, Blicher T, Rosenlund S, Eriksson J, Heller S, Hels O . Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019; 7(7):515-527. DOI: 10.1016/S2213-8587(19)30192-5. View

19.

van Ruiten C, van der Aart-van der Beek A, IJzerman R, Nieuwdorp M, Hoogenberg K, van Raalte D . Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial. Diabetes Obes Metab. 2021; 23(8):1851-1858. PMC: 8360098. DOI: 10.1111/dom.14410. View

20.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View